{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:40:21Z","timestamp":1789800021217,"version":"4.0.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neuromyelitis optica spectrum disorders (NMOSD) are demyelinating diseases of the central nervous system, have drawn the attention of many researchers due to the relapsing courses and cumulative disability. A first bibliometric analysis of NMOSD was conducted to identify the research hotspots and emerging trends. Articles relevant to NMOSD published in the core collection of Web of Science were retrieved and analyzed through visualized analysis using CiteSpace and VOSviewer, focusing on annual publication trends, countries, institutions, authors, journals, and keywords. The analysis showed that over the past 30 years, publications related to NMOSD had shown steady growth with slight fluctuations. The United States played an important part in this field, with the highest outputs and the greatest number of citations. Research hotspots of NMOSD had gradually shifted from the definition, biomarkers, and diagnostic criteria to diagnosis and treatment, particularly immunotherapy. This bibliometric analysis provides researchers with a theoretical basis for studying NMOSD and offers guidance for future research directions.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1135061","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T14:01:52Z","timestamp":1689256912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo-Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Hui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Ji","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Shi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/icu.0000000000000703","article-title":"Update on neuromyelitis optica spectrum disorder","volume":"31","author":"Holroyd","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000021828","article-title":"A bibliometric analysis of income and cardiovascular disease: status, hotspots, trends and outlook","volume":"99","author":"Ding","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101311","article-title":"The future landscape of macrophage research in cardiovascular disease: a bibliometric analysis","volume":"47","author":"Xu","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.3390\/ijerph19031893","article-title":"Predicting infectious diseases: a bibliometric review on Africa","volume":"19","author":"Phoobane","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.3390\/ijerph17176218","article-title":"The prediction of infectious diseases: a bibliometric analysis","volume":"17","author":"Yang","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060382","article-title":"Advances in breast cancer management and extracellular vesicle research, a bibliometric analysis","volume":"28","author":"Teles","year":"2021","journal-title":"Curr Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.03.045","article-title":"Bibliometric analysis of global research on pd-1 and pd-L1 in the field of cancer","volume":"72","author":"Gao","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12951-021-01150-6","article-title":"An overview and bibliometric analysis on the colorectal cancer therapy by magnetic functionalized nanoparticles for the responsive and targeted drug delivery","volume":"19","author":"Darroudi","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106775","article-title":"One hundred most cited article related to pancreaticoduodenectomy surgery: a bibliometric analysis","volume":"104","author":"He","year":"2022","journal-title":"Int J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.927219","article-title":"Bibliometric analysis of global research on cancer photodynamic therapy: focus on nano-related research","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101213","article-title":"Bibliometric analysis on the progress of chronic heart failure","volume":"47","author":"Wang","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910444","article-title":"A bibliometric and knowledge-map analysis of macrophage polarization in atherosclerosis from 2001 to 2021","volume":"13","author":"Song","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/wnl.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1017\/iop.2020.2","article-title":"Prestige and relevance of the scholarly journals: impressions of siop members","volume":"13","author":"Highhouse","year":"2020","journal-title":"Ind Organizational Psychol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10783-4","article-title":"Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders","volume":"269","author":"Abboud","year":"2022","journal-title":"J Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00295-8","article-title":"Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Wingerchuk","year":"2022","journal-title":"Neurol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(04)17551-x","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6594-3","article-title":"On the contribution of Thomas Clifford allbutt, F.R.S., to the early history of neuromyelitis optica","volume":"260","author":"Jarius","year":"2013","journal-title":"J Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (Nmo-igg) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0074-7742(07)79029-3","article-title":"Neuromyelitis optica: new findings on pathogenesis","volume":"79","author":"Wingerchuk","year":"2007","journal-title":"Neurobiol Multiple Sclerosis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood gfap as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00281-022-00941-9","article-title":"Immuno-pathogenesis of neuromyelitis optica and emerging therapies","volume":"44","author":"Chihara","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (Nmosd): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 igg-positive nmosd","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (Rin-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-momentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (Tango): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13836","article-title":"Progress in treatment of neuromyelitis optica spectrum disorders (Nmosd): novel insights into therapeutic possibilities in nmosd","volume":"28","author":"Shi","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ncl.2020.09.003","article-title":"Advances in the treatment of neuromyelitis optica spectrum disorder","volume":"39","author":"Wallach","year":"2021","journal-title":"Neurol Clin"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-Positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"New Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.06.008","article-title":"New treatment perspectives for acute relapses in neuromyelitis optica spectrum disorder","volume":"36","author":"Lotan","year":"2022","journal-title":"Transfusion Med Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1212\/con.0000000000001168","article-title":"Neuromyelitis optica spectrum disorders","volume":"28","author":"Costello","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084154","article-title":"Adverse events in nmosd therapy","volume":"23","author":"Giglhuber","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155304","article-title":"Hematopoietic stem cell transplantation in neuromyelitis optica-spectrum disorders (Nmo-sd): state-of-the-Art and future perspectives","volume":"21","author":"Ceglie","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-bcma car T-cell therapy Ct103a in relapsed or refractory Aqp4-igg seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.690537","article-title":"Multi-level analyses of genome-wide association study to reveal significant risk genes and pathways in neuromyelitis optica spectrum disorder","volume":"12","author":"Li","year":"2021","journal-title":"Front Genet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000004","article-title":"Predictors of recurrence following an initial episode of transverse myelitis","volume":"1","author":"Kimbrough","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the united kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in Aqp4-igg positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873576","article-title":"Neuromyelitis optica spectrum disorder with anti-Aquaporin-4 antibody: outcome prediction models","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1135061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T14:01:54Z","timestamp":1689256914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1135061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2023.1135061"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1135061","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"article-number":"1135061"}}